Supplementary materialBGEN-S-10-00087

Effect of infection on tissue protein synthesis in initially non-inflamed and low-grade inflamed old rat

Treatment / Control / Infection D10 / Infection D23 / Two-way ANOVA
Initial inflammatory status / Non-inflamed / Low-grade inflamed / Non-inflamed / Low-grade inflamed / Non-inflamed / Low-grade inflamed
Sub-group (n) / NI-Con0 (11) / LGI-Con0 (9) / NI-Inf10 (8) / LGI-Inf10 (10) / NI-Inf23 (10) / LGI-Inf23 (10)
Gastrocnemius
Proteins (mg) / 409 ± 14 / 417 ± 18 / 360 ± 13 / 364 ± 16 / 353 ± 22 / 303 ± 24 / T
ks (%/d) / 3.75 ± 0.29 / 3.54 ± 0.39 / 4.20 ± 0.63 / 3.72 ± 0.44 / 5.13 ± 0.39 / 5.08 ± 0.34 / T
Cs (mg RNA/g prot) / 8.60 ± 0.24 / 8.55 ± 0.37 / 8.66 ± 0.53 / 8.93 ± 0.44 / 8.54 ± 0.48 / 8.93 ± 0.52 / ns
kRNA (g/d/g RNA) / 4.36 ± 0.31 / 4.24 ± 0.51 / 4.91 ± 0.75 / 4.31 ± 0.59 / 6.01 ± 0.32 / 5.90 ± 0.53 / T
Liver
Proteins (mg) / 2430 ± 121 a / 2468 ± 74 a / 1729 ± 78 b / 2481 ± 104 a / 2028 ± 80 c / 2285 ± 108 ac / I, T, TxI
ks (%/d) / 56.4 ± 1.1 / 63.3 ± 2.6 / 66.0 ± 2.7 / 71.6 ± 3.1 / 66.6 ± 2.3 / 65.5 ± 2.0 / I (P=0.053), T
Cs (mg RNA/g prot) / 60.2 ± 1.5 / 70.4 ± 2.9 / 73.2 ± 1.7 / 74.6 ± 1.1 / 69.9 ± 2.3 / 72.3 ± 2.5 / I, T, TxI (P=0.072)
kRNA (g/d/g RNA) / 9.45 ± 0.35 / 9.02 ± 0.23 / 9.02 ± 0.31 / 9.60 ± 0.40 / 9.55 ± 0.22 / 9.12 ± 0.34 / ns
Jejunal mucosa
Proteins (mg/ 10 cm) / 31.6 ± 1.0 / 35.1 ± 2.6 / 28.4 ± 2.6 / 29.0 ± 1.4 / 35.8 ± 2.4 / 39.5 ± 1.9 / T
ks (%/d) / 84.2 ± 2.8 / 80.5 ± 2.8 / 81.3 ± 3.7 / 77.2 ± 3.7 / 91.1 ± 3.7 / 89.0 ± 6.0 / T
Cs (mg RNA/g prot) / 81.0 ± 2.0 / 83.2 ± 8.5 / 86.3 ± 9.1 / 74.5 ± 2.1 / 86.1 ± 4.2 / 85.9 ± 4.9 / ns
kRNA (g/d/g RNA) / 10.5 ± 0.5 / 10.3 ± 0.9 / 9.9 ± 0.7 / 10.5 ± 0.7 / 10.8 ± 0.7 / 10.4 ± 0.5 / ns
Spleen
Proteins (mg) / 214 ± 16 / 279 ± 21 / 229 ± 20 / 332 ± 29 / 334 ± 31 / 355 ± 31 / I, T
ks (%/d) / 29.8 ± 2.4 / 35.8 ± 5.1 / 39.3 ± 4.5 / 40.7 ± 3.7 / 37.4 ± 2.0 / 41.4 ± 3.5 / T (P=0.089)
Cs (mg RNA/g prot) / 40.4 ± 5.1 / 41.8 ± 6.8 / 39.3 ± 2.3 / 41.0 ± 2.0 / 37.6 ± 3.3 / 39.6 ± 5.9 / ns
kRNA (g/d/g RNA) / 8.00 ± 0.62 / 8.71 ± 0.51 / 10.09 ± 1.25 / 9.89 ± 0.60 / 10.69 ± 1.31 / 12.17 ± 1.44 / T
Kidneys
Proteins (mg) / 409 ± 19 / 540 ± 58 / 391 ± 17 / 594 ± 33 / 421 ± 20 / 546 ± 38 / I
ks (%/d) / 28.7 ± 0.50 / 30.0 ± 1.3 / 28.6 ± 1.5 / 32.4 ± 1.5 / 31.0 ± 0.7 / 29.7 ± 1.0 / TxI (P=0.067)
Cs (mg RNA/g prot) / 36.2 ± 2.7 / 32.8 ± 3.1 / 38.6 ± 3.3 / 37.0 ± 2.4 / 35.8 ± 1.1 / 30.0 ± 1.6 / I (P=0.078)
kRNA (g/d/g RNA) / 8.18 ± 0.51 / 9.46 ± 0.87 / 7.65 ± 0.57 / 9.09 ± 0.76 / 8.80 ± 0.34 / 10.02 ± 0.81 / I
Bone marrow
Proteins (mg/ 2 tibias) / 15.0 ± 1.4 / 17.0 ± 1.7 / 15.0 ± 1.2 / 17.0 ± 1.2 / 16.5 ± 1.2 / 21.2 ± 1.1 / I, T (P=0.057)
ks (%/d) / 74.6 ± 3.6 / 73.2 ± 3.7 / 97.7 ± 4.7 / 89.1 ± 2.8 / 82.4 ± 1.3 / 76.0 ± 4.3 / I (P=0.061), T
Cs (mg RNA/g prot) / 124 ± 4 / 136 ± 5 / 135 ± 4 / 131 ± 5 / 131 ± 3 / 127 ± 5 / ns
kRNA (g/d/g RNA) / 6.11 ± 0.45 / 5.40 ± 0.16 / 7.30 ± 0.43 / 6.86 ± 0.30 / 6.33 ± 0.22 / 6.02 ± 0.38 / I (P=0.091), T

Means ± SE. Two-way (initial inflammatory status and treatment) ANOVA: ns: non-significant effect, T and I: significant effect of treatment and initial inflammatory status, respectively; TxI: significant interaction between treatment and initial inflammatory status; P≤ 0.05. P value is in parentheses when a trend is observed. Within a row, values not sharing a common superscript letter are significantly different (Fisher’s PLSD test). ks: fractional rate of protein synthesis, Cs: capacity for protein synthesis, kRNA: efficiency of translation.